Objective: To determine whether treatment with creatine can improve exercise intolerance in myophosphorylase deficiency (McArdle disease).
M
CARDLE DISEASE is a rare autosomal recessive metabolic myopathy caused by a defect of the muscle-specific isozyme of glycogen phosphorylase that leads to a blockade of adenosine triphosphate (ATP) formation from glycogen in skeletal muscle. The defect in the glycogen breakdown pathway leads to deprivation of an important energy source, particularly during the early stages of exercise when the availability of fatty acids for oxidation is limited. Typically, patients with McArdle disease have exercise intolerance with premature fatigue, exercise-induced muscle pain in working muscles, and recurrent myoglobinuria, which usually start in childhood. Treatments for McArdle disease have been unsatisfactory. 1 Creatine is a naturally occurring compound. Interconversion between creatine (Cr) and phosphocreatine (PCr) is catalyzed by creatine kinase: PCr + ADP ↔ ATP + Cr, where ADP indicates adenosine diphosphate. This reaction is near equilibrium in skeletal muscle and is important in buffering ATP against changing energy demand 2, 3 and in determining ADP, an important regulating factor in processes like oxidative phosphorylation. 4 Net phosphocreatine hydrolysis provides ATP directly in the early stages of exercise. 5 The intake of exogenous creatine, in doses of 10 to 20 g daily was well tolerated and resulted in an average increase of approximately 20% of total creatine and phosphocreatine in skeletal muscle. 6 In healthy individuals and in patients with mitochondrial cytopathies, creatine supplementation improved exercise performance during repeated bouts of maximal-intensity exercise. [7] [8] [9] [10] [11] [12] [13] We hypothesized that creatine monohydrate supplementation for patients with McArdle disease would improve exercise intolerance and be well tolerated. To address this issue, we performed the present doubleblind, placebo-controlled crossover trial in 9 patients with McArdle disease. 
PATIENTS AND METHODS

PATIENTS
Nine patients (6 women, 3 men; mean ± SD age, 39.1 ± 17.9 years) with biochemically and genetically proven McArdle disease entered the trial. 14 All patients had clinical features of exercise intolerance, defined as early fatigue and exerciseinduced muscle pain in working muscle. Of the 9 patients, 3 (patients 1, 7, and 8) had fixed proximal weakness ( Table 1) . All patients led a normal life but were limited in daily activities, such as walking uphill and climbing stairs, and they could not carry out vigorous activities. Written informed consent was obtained from all patients after the study had been fully explained. The ethics committee of the University of Bochum, Bochum, Germany, approved the study protocol.
STUDY DESIGN
Patients were randomly assigned to receive either creatine capsules or placebo capsules. One group took creatine capsules, 150 mg/kg body weight daily for 1 week, followed by 60 mg/kg body weight daily (Figure 1) . The other group took the same amount of an identical-looking placebo for the same period. Each treatment phase lasted 5 weeks. Both phases were separated by a 4-week washout period. The capsules contained either creatine monohydrate, 750 mg, or lactose (placebo), 750 mg, and were taken in 3 divided doses with major meals. Creatine and placebo capsules were generously provided by ViaNova (Waltenhofen, Germany). At the final day of each treatment period, clinical measurements and laboratory studies were performed first, followed by surface electromyography (S-EMG), ergometer exercise test, and finally phosphorus 31 nuclear magnetic resonance (NMR) spectroscopy.
CLINICAL RATING SCALES
The clinical rating scales were devised to describe the clinical symptoms of exercise intolerance. The fatigue severity scale (FSS) 16 was administered to quantify early fatigue on exertion. Higher scores indicated worse performing, with a maximum score of 63 indicating worst functioning, and a score of 7 indicating normal performance. Severity of exerciseinduced muscle pain in working muscles was graded using the following system: 0, none; 1, slight (painful, but no functional impairment); 2, moderate (painful, functionally impairing); and 3, severe (very painful, patient must rest). Each patient was asked to indicate the frequency (bouts) of muscle pain: 0, none; 1, sporadic (Ͻ1 bout per week); 2, frequent (2-7 bouts per week); and 3, very frequent (Ͼ7 bouts per week).
LABORATORY STUDIES
Blood samples were taken from an antecubital vein before and at the end of each treatment period. Creatine levels were determined colorimetrically using an enzymatic method.
17
ERGOMETER EXERCISE TEST
Ergometric tests were performed on an electrically braked bicycle ergometer. The test began with 6 minutes of rest while the subjects sat on the ergometer followed by exercising 3 minutes at a work rate of 25 W. Work rates were then increased every 3 minutes by 25 W. Exercise was continued until severe general or leg fatigue was prominent or until the submaximal heart rate of 200 − age (in years) was obtained. Maximal workload and maximal duration of ergometer exercise were measured.
PHOSPHORUS 31 NMR SPECTROSCOPY
Phosporus 31 NMR spectroscopy, exercise protocol, and analysis of 31 P-NMR data were identical to a previous report. 18 The NMR spectra were obtained in a 4.7-T, 40-cm horizontal bore spectrometer (Bruker-Biospec 47/40; BrukerMedizintechnik, Karlsruhe, Germany), using a 5-cm diameter surface coil placed under the right calf muscle. The patients were placed in the supine position with the upper body elevated by 25°. The foot was fixed on a pedal ergometer designed for isometric foot plantar flexion exercise. Arterial occlusion was induced using an air cuff placed around the lower part of the right thigh, which was rapidly inflated to 280 to 300 mm Hg using compressed air. Isometric maximum voluntary contraction (MVC) of foot plantar flexion was determined as the highest of 3 contractions. Energy metabolism was continuously monitored during rest and static plantar flexion exercise of 30% MVC under natural perfusion and under applied ischemia (Figure 2) . Since all patients voluntarily hold muscle force during exercise and easy fatigability is a cardinal feature of McArdle disease, variations in force could not be avoided. Therefore, 
EFFECT OF TREATMENT
All 9 enrolled patients completed the 14-week study, and clinical rating scores were taken from all patients. Except for slight headache and dizziness during the first 4 days of the creatine phase in patient 3, no relevant adverse effects were noted. The FSS scores at the end of the creatine and placebo phases did not differ significantly (P=.54). There was no change in muscle strength in the 3 patients with fixed proximal weakness. Of the 9 patients, 5 reported subjective improvement of severity of muscle pain with creatine and wanted to continue taking it. The remaining 4 patients had a lower frequency of muscle pain with creatine. Patient 9 reported improvement in severity and frequency of muscle pain with placebo. Patient 8 reported a lower frequency of muscle pain with placebo, but no change in severity of muscle pain. In patients 1 and 2, severity and frequency of muscle pain did not change ( Table 2) . However, taking all patients together, the comparison of changes in clinical scores at the end of the creatine vs placebo phases indicated no significant improvement of muscle pain with creatine use. Laboratory studies were performed in all patients but one (patient 5), who refused regular blood studies. Oral creatine caused a significant increase in the plasma level of creatine (P=.01). Creatine kinase values did not change significantly with creatine use (P=.16) (range at baseline, 53-12 630 U/L; normal, Ͻ80 U/L). Ergometer exercise test results were recorded for 7 patients; 2 patients (patients 1 and 7) were unable to perform the protocol (Table 2 ). Statistical analysis detected no significant force-time integrals were calculated for the aerobic as well as ischemic exercise period and given in newton-minutes. Metabolite levels were expressed as percentage of phosphocreatine at initial rest. Absolute metabolite concentrations in millimoles per liter of cell water were calculated assuming that during the initial phase of rest, the value of ATP is 8.2 mmol/L. 19 The concentration of ADP and the intracellular pH were determined as previously described. [19] [20] [21] The time constants for phosphocreatine recovery were measured after aerobic (1) as well as ischemic (2) contraction. The changes of metabolite levels for phosphocreatine, ATP, and pH during the aerobic as well as ischemic exercise were calculated as differences of the values at the beginning of exercise minus those at the end of exercise. The changes of metabolite levels for ADP, phosphomonoester (PME), and inorganic phosphate (Pi) were measured as differences of the values at the end of exercise minus those at the beginning of exercise. Typical 
SURFACE ELECTROMYOGRAPHY
The S-EMG was derived from the right gastrocnemius muscle during isometric foot plantar flexion. The experimental setup was similar to that used for 31 P-NMR. The patients performed a contraction of 30% MVC for about 2.5 minutes. The S-EMG was recorded by surface electrodes placed about 20 cm above the ankle joint over the gastrocnemius muscle in the direction of the muscle fibers. The raw EMG was recorded on an analog magnetic tape (bandwidth, 0 to 1.2 kHz) and evaluated offline. The signals underwent band-pass filtering between 3 and 500 Hz and analog-digital conversion with a sample rate of 1024 Hz. The time courses for the root mean square (RMS) as a measure of the EMG amplitude and for the median frequency (MF) characterizing the EMG spectral distribution were calculated as previously described. 22, 23 A typical S-EMG time course is shown in Figure 4 .
STATISTICS
The analysis of all continuous parameters of interest (FSS, laboratory studies, ergometer exercise test, S-EMG, and 31 P-NMR) was performed in a standard way for crossover trials, with 2-sample t tests for the intraindividual period differences, assuming no carryover effects and at most equal period effects (2-sided ␣=.05). 24 For each parameter, we included the maximum number of patients available (9 for FSS, 8 for laboratory studies, and 7 for the ergometer exercise test, S-EMG, and 31 P-NMR). For the clinical rating scores of muscle complaints, we performed the sign test on the intraindividual period differences (neglecting group membership and hence having to assume no period effects). All analyses were performed using SAS statistical software version 6.12 (SAS Institute Inc, Cary, NC). (REPRINTED) ARCH NEUROL / VOL 57, JULY 2000 WWW.ARCHNEUROL.COM 958 differences in maximum workload (P=.68) and in maximal duration of exercise (P=.70).
P-NMR SPECTROSCOPY
The 31 P-NMR data were evaluated in 7 of the 9 patients. In patients 1 and 9, 31 P-NMR could not be recorded; the patients could not fit in the spectrometer because they were overweight. For the mean levels of all measured values at initial rest, there was no significant difference with creatine use (phosphocreatine, P = .15; PME, P = .87; ADP, P = .30; Pi, P = .76; and pH, P = .81) ( Table 3) . Furthermore, creatine did not significantly alter the time courses of ATP (P = .64), ADP (P = .33), and pH (P = .53) values during aerobic exercise or the time courses of ATP (P = .19), ADP (P = .11), and pH (P=.66) values during ischemic exercise. The time constants of oxidative phosphocreatine recovery from aerobic (P = .45) and ischemic (P = .60) exercise also were not significantly different from those with placebo. However, during ischemic exercise, the force-time integral was significantly higher with creatine (P = .03). Consequently, phosphocreatine depletion (P=.04) and the accumulation of Pi (P = .046) increased during ischemic exercise with creatine. In addition, during aerobic exercise with creatine, a significant increase was observed in phosphocreatine depletion (P=.006) and a trend toward increase of Pi elevation (P = .09). The force-time integrals during aerobic exercise did not change significantly (P=.22) ( Table 3) . Force-time integrals varied considerably among the patients ( Figure 5 ). Force-time integrals increased with creatine in 4 of the 7 patients during aerobic exercise and in 6 of the 7 patients during ischemic exercise. Phosphocreatine consumption increased in 5 of the 7 patients during ischemic as well as aerobic exercise with creatine. A concomitant elevation of Pi resulting from phosphocreatine breakdown was also measured in 5 patients during aerobic as well as ischemic exercise with creatine.
SURFACE ELECTROMYOGRAPHY
Surface electromyograms were evaluated for 7 of the 9 patients. For patients 7 and 8, data analysis was not possible because the signal intensities were too weak. For all patients and both treatment phases, a negative slope for MF was found, indicating a shift in the frequency spectrum to lower frequencies over time. For RMS, a positive slope was observed for all persons, with the exception of patient 1, in whom a small negative slope was found with placebo (Table 3) . Thus, in almost all cases, a clear increase in the EMG amplitude was observed during sustained contraction. The individual differences for the slopes after ingesting creatine and placebo are shown in Table 3 and Figure 6 . A uniform influence of creatine was established for MF; its decrease over time was steeper with creatine for all patients with the exception of patient 2. However, the influence of creatine on the RMS slope was nonuniform. Statistical analysis revealed a significant influence of creatine on the MF slope (P=.03).
COMMENT
This is the first direct investigation of the effects of creatine ingestion in patients with McArdle disease. Dietary creatine supplementation caused a substantial increase in the plasma concentration of creatine and was well tolerated. This is in agreement with previous studies showing that short-term and long-term oral creatine ingestion at a dosage up to 20 g/d causes no adverse ef- fects and significantly increases plasma creatine values. [7] [8] [9] [10] [11] [12] Muscle contraction, ion transport, and ATP hydrolysis are coupled by specific adenosine triphosphatases (ATPases); for example, myofibrillar, calcium (Ca reduced substrate availability, and glycolysis is virtually absent, causing a severe limitation in the maximal rate of ATP resynthesis. 25, 26 Despite the limited capacity for ATP resynthesis, little or no decline in muscle ATP has been observed during fatiguing exercise in McArdle disease. [27] [28] [29] [30] Therefore, exercise intolerance cannot simply be explained by a lack of energy supply to the contractile mechanisms of muscle. Other factors, like alterations in the energy metabolism of membrane excitation and limitation of phosphocreatine breakdown, must be considered. 25, 28, 31 *Group 1 (n = 4) received placebo as allocated in the first treatment phase and creatine in the second treatment phase. Group 2 (n = 5) received creatine as allocated in the first treatment phase and placebo in the second treatment phase. Ellipses indicate data not applicable; ⌬, period differences between the first and second treatment phases. *Group 1 (n = 4) received placebo as allocated in the first treatment phase and creatine in the second treatment phase. Group 2 (n = 5) received creatine as allocated in the first treatment phase and placebo in the second treatment phase. NMR indicates nuclear magnetic resonance; S-EMG, surface electromyogram; ellipses, data not available; ⌬, period differences between the first and second treatment phases; PCr, phosphocreatine; Pi, inorganic phosphate; ATP, adenosine triphosphate; ADP, adenosine diphosphate; PME, phosphomonoester; RMS, root mean square; and MF, median frequency.
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To our knowledge, this study is the first to provide objective evidence that creatine supplementation improves exercise performance in McArdle disease, mainly during ischemic exercise. This is a combined effect of an increase in MVC and in the ability to maintain 30% MVC for a longer period before fatigue. This enhanced exercise performance is associated with increased intramuscular phosphocreatine use. The precise physiological mechanisms underlying this ergogenic action of creatine remain to be clarified. Although the blood concentration of creatine significantly increased with creatine supplementation, we could not demonstrate a significant increase in muscle phosphocreatine content. Therefore, the therapeutic changes of creatine are not mediated through elevated intramuscular phosphocreatine, but may involve other factors, like enhanced energy shuttling, stimulation of mitochondrial respiration, stabilization of mitochondrial creatine kinase, or improvements primarily at the neuronal system. 32 The S-EMGs in this study are characterized by an increase in RMS and a decrease in MF over time. Such changes are typically found during fatiguing muscle contractions. In normal subjects, an accumulation of potassium in the extracellular space has been regarded as the main reason for fatigue-induced changes in the EMG. 33, 34 In McArdle disease, this effect is enhanced, since Na + K + -ATPase is reduced 35 and the blood potassium concentration during exercise significantly increased. 35, 36 Such an increase in the extracellular potassium concentration results in reduced excitability of the muscle fiber membrane as well as a decrease in the action potential amplitude. [37] [38] [39] Accordingly, the force per action potential decreases. 40 In this study, S-EMG revealed an enhanced time-related decrease in MF with creatine administration. This might indicate that creatine also affects factors controlling the electrical parameters of the action potential and the excitability of the muscle fiber membrane. Whether these myoelectrical changes contribute primarily to the improved exercise performance remains to be established.
In summary, the short-term creatine monohydrate supplementation was well tolerated, enhanced submaximal working capacity, and may have improved exerciseinduced muscle pain in McArdle disease. These results point to a possible new symptomatic therapy in this glycogenolytic disorder. Further trials are needed to confirm this therapeutic effect.
